YHYoshio Hirota

Yoshio Hirota

*This is an algorithmically generated author record based on publicly available information.

Yoshio Hirota has a total of 133 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Validation of the Modified Japanese 7C Readiness Scale for Parental Intentions of Child COVID-19 Vaccination

    by Mikiko Tokiya, Akiko Matsumoto, Yutaro Furukawa, Takaomi Kobayashi, Takashi Nakano, Yoshio Hirota, Megumi Hara

    Parental willingness is a prerequisite for childhood immunization. This study evaluated whether parental vaccination readiness and willingness, measured using the modified Japanese 7C Vaccination Readiness Scale, predicted vaccination behavior. In December 2021, 2 months before the approval of COVID-19 vaccines for children aged 5–11 years in Japan, 1190 parents of children in this age group were surveyed regarding their intention to vaccinate their children against COVID-19. The survey utilized an online version of the modified 7C Vaccination Readiness Scale, comprising seven components: Confidence, Complacency, Constraints, Calculation, Collective Responsibility, Compliance, and Conspiracy. The modified 7C components were analyzed for model fit and their association with parental intention using structural equation modeling. The scale demonstrated good model fit (goodness-of-fit index: 0.98), with high standardized factor loadings for parental readiness (factor loadings: 0.84). In January 2024, the same parents were surveyed about their children’s COVID-19 vaccination status (valid responses: 536). The relationship between the components of the modified 7C scale and actual vaccination behavior was examined. Parents with low readiness to vaccinate their children against COVID-19 exhibited a significantly higher non-vaccination rate. These findings suggest that the modified 7C scale could support the development of targeted interventions to improve childhood vaccination uptake.


  • Open Access

    Impact of Pre-Vaccination Active Vitamin D Levels on COVID-19 mRNA Vaccine-Induced Immunity in a Japanese Cohort

    by Tomoaki Hirakawa, Goki Yamada, Mikiko Tokiya, Takuma Furukawa, Chiharu Iwasaka, Takeshi Sawada, Tadayuki Tsujita, Mizuho A Kido, Yoshio Hirota, Megumi Hara, et al.

    Background/Objectives: Low blood vitamin D levels have been linked to COVID-19 severity; however, data on the effects of vitamin D on vaccine immunogenicity remain limited. This study evaluated the impact of baseline serum 1α, 25-(OH)2 vitamin D, a bioactive form with controlled blood concentrations, on vaccine response. Methods: From June to September 2021, we measured active vitamin D levels in 88 Japanese workers and students before vaccination with BNT162b2 or mRNA-1273. We assessed SARS-CoV-2 spike protein S1 IgG and IgM levels and antigen-specific INF-γ-releasing cells from pre-vaccination up to 8 months post-second dose. Results: Active vitamin D levels ranged from 33.7 to 99.8 pg/mL, 60.2% above the Japanese reference range (20–60 pg/mL). In a mixed model accounting for repeated measures and sub-cohort random effects and following fixed effects, vaccine type, weeks post-vaccination, age, sex, ALDH2 gene polymorphism, height, smoking, ethanol intake, exercise, stress, steroid use, allergies, dyslipidemia, active vitamin D was negatively associated with anti-S1 IgG and IgM (p < 0.001) but positively with INF-γ-releasing cell counts (p = 0.003). Conclusions: As the robustness of cellular immunity is independent of viral mutations, 1,25-(OH)2 vitamin D levels above the reference range may enhance vaccine-induced COVID-19 protection in the long term.

  • Open Access

    Assessing Parental Intention to Vaccinate their Children Against COVID-19: Validation of the Modified Japanese 7C Vaccination Readiness Scale

    by Mikiko Tokiya, Akiko Matsumoto, Yutaro Furukawa, Takaomi Kobayashi, Takashi Nakano, Yoshio Hirota, Megumi Hara

    Parental willingness is a prerequisite for childhood immunization. This study evaluated whether parental vaccination readiness and willingness, measured using the modified Japanese 7C Vaccination Readiness Scale, predicted vaccination behavior. In December 2021, 2 months before the approval of COVID-19 vaccination for children aged 5–11 years in Japan, we asked 1,190 parents of children in this age groups about their intention regarding vaccinating their children against COVID-19 using an online modified 7C Vaccination Readiness Scale, consisting of seven components, namely, Confidence, Complacency, Constraints, Calculation, Collective responsibility, Compliance, and Conspiracy. The modified 7C components were analyzed for model fit and association with parental intention using structural equation modeling. The model fit of the modified 7C scale was good (goodness-of-fit index: 0.98), and the factor loadings and model fit for parental readiness were high (standardized factor loadings: 0.84). In January 2024, we asked the same parents about their children's COVID-19 vaccination status (valid responses: 536). The components of the modified 7C scale were compared with actual vaccination behavior. Parents with a low readiness to vaccinate their children against COVID-19 had a high actual non-vaccination rate. The use of the modified 7C scale may assist in the development of childhood vaccination interventions.

  • Open Access

    Asian Flush Gene Variant Enhances Cellular Immunogenicity of COVID-19 Vaccine: Prospective Observation in the Japanese General Population

    by Sudarma Bogahawaththa, Megumi Hara, Takuma Furukawa, Chiharu Iwasaka, Takeshi Sawada, Goki Yamada, Mikiko Tokiya, Kyoko Kitagawa, Yasunobu Miyake, Mizuho Aoki Kido, et al.

    We previously reported a reduced humoral immune response to the COVID-19 vaccines. Subsequently, we observed a lower susceptibility to COVID-19 in individuals carrying the ALDH2 rs671 variant through a web-based retrospective survey. Based on these findings, we hypothesized that rs671 variant was beneficial for cellular immunity against COVID-19. Using the IFN-γ enzyme-linked immunospot (ELISPOT) assay, we assessed cellular immunity before and after COVID-19 vaccination in two subcohorts of a previously reported cohort. Subcohort 1 (26 participants) had six repeated observations at baseline after one to three doses, whereas subcohort 2 (19 participants) had two observations before and after the third dose. ELISPOT counts at six months after the second dose increased from baseline in carriers of the rs671 variant but not in non-carriers. A positive effect of rs671 on ELISPOT counts was estimated using a mixed model (183 observations from 45 participants), including the random effect of subcohort, repeated measures, and fixed effects of vaccine type, age, sex, height, lifestyle, steroid use, and allergic disease. There was no association between ELISPOT counts and specific IgG levels, suggesting a limitation in estimating protective potential by humoral response. Our sequential observational studies suggest a beneficial effect of the rs671 variant in SARS-CoV-2 infection via enhanced cellular immune response, providing a potential basis for optimizing preventive measures and drug development.


  • Open Access

    Asian Flush Gene Variant Enhances Cellular Immunogenicity of COVID‐19 Vaccine: Prospective Study in the Japanese General Population

    by Sudarma Bogahawaththa, Megumi Hara, Takuma Furukawa, Chiharu Iwasaka, Takeshi Sawada, Goki Yamada, Mikiko Tokiya, Kyoko Kitagawa, Yasunobu Miyake, Yoshio Hirota, et al.

    Because we observed a reduced humoral immune response to the COVID-19 vaccine and subsequently discovered a lower susceptibility to COVID-19 in individuals carrying the ALDH2 rs671 variant, we hypothesized that rs671 is beneficial for cellular immunity against COVID-19. Using the IFN-γ enzyme-linked immunospot (ELISPOT) assay, we evaluated cellular immunity before and after COVID-19 vaccination in two subcohorts of a previously reported cohort. Subcohort 1 (26 participants) had six repeated observations at baseline and after one to three doses, whereas subcohort 2 (19 participants) had two observations, before and after the third dose. ELISPOT counts at six months after the second dose increased from baseline in carriers of the rs671 variant, but not in non-carriers. A positive effect of rs671 on ELISPOT counts was estimated using a mixed model, including the random effect of subcohort, repeated measures, and fixed effects of vaccine type, age, sex, height, lifestyle, steroid use, and allergic disease. There was no association between ELISPOT counts and specific IgG levels, suggesting a limitation in estimating protective potential by humoral response. There is lower humoral and higher cellular immunity against SARS-CoV-2 in rs671 variant carriers compared to non-carriers, providing a potential basis for optimizing preventive measures and drug discovery.


  • Alcohol

    by Wakaba Fukushima, Yoshio Hirota

  • Trajectory analyses to identify persistently low responders to COVID-19 vaccination in patients with inflammatory bowel disease: a prospective multicentre controlled study, J-COMBAT

    by Kenji Watanabe, Masanori Nojima, Hiroshi Nakase, Toshiyuki Sato, Minoru Matsuura, Nobuo Aoyama, Taku Kobayashi, Hirotake Sakuraba, Masakazu Nishishita, Kaoru Yokoyama, et al.

    Background The degree of immune response to COVID-19 vaccination in inflammatory bowel disease (IBD) patients based on actual changes in anti-SARS-CoV-2 antibody titres over time is unknown. Methods Data were prospectively acquired at four predetermined time points before and after two vaccine doses in a multicentre observational controlled study. The primary outcome was humoral immune response and vaccination safety in IBD patients. We performed trajectory analysis to identify the degree of immune response and associated factors in IBD patients compared with controls. Results Overall, 645 IBD patients and 199 control participants were analysed. At 3 months after the second vaccination, the seronegative proportions were 20.3% (combination of anti-tumour necrosis factor [TNF]α and thiopurine) and 70.0% (triple combination including steroids), despite that 80.0% receiving the triple combination therapy were seropositive at 4 weeks after the second vaccination. Trajectory analyses indicated three degrees of change in immune response over time in IBD patients: high (57.7%), medium (35.6%), and persistently low (6.7%). In the control group, there was only one degree, which corresponded with IBD high responders. Older age, combined anti-TNFα and thiopurine (odds ratio [OR], 37.68; 95% confidence interval [CI], 5.64–251.54), steroids (OR, 21.47; 95%CI, 5.47–84.26), and tofacitinib (OR, 10.66; 95%CI, 1.49–76.31) were factors associated with persistently low response. Allergy history (OR, 0.17; 95%CI, 0.04–0.68) was a negatively associated factor. Adverse reactions after the second vaccination were significantly fewer in IBD than controls (31.0% vs 59.8%; p < 0.001). Conclusions Most IBD patients showed a sufficient immune response to COVID-19 vaccination regardless of clinical factors. Assessment of changes over time is essential to optimize COVID-19 vaccination, especially in persistently low responders. Graphical abstract


  • Comparison of BNT162b2 and mRNA1273 vaccines in solid organ transplant recipients: Post‐Hoc analysis of a Japanese national prospective study

    by Mikiko Yoshikawa, Yoichiro Natori, Rikako Oki, Kohei Unagami, Satoko Ohfuji, Ryoichi Imamura, Hideki Ishida, Shiro Takahara, Yoshio Hirota, Hiroto Egawa

    The coronavirus disease‐19 (COVID‐19) vaccine efficacy and immunogenicity in the immunocompetent population are well established. However, in solid organ transplant (SOT) recipients, because of their use of immunosuppressive medication, the immunogenicity of these severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) vaccines remains suboptimal. Both BNT162b2 and mRNA1273 have been used for some time, but their immunogenicity has not been directly compared in this immunocompromised patient group. We performed a post‐hoc analysis of a previous prospective cohort study. The inclusion criteria were adult SOT recipients with active grafts at least 1 month after SOT. After giving consent, participants chose to receive either BNT162b2 or mRNA1273 vaccine. Anti‐spike‐protein‐S antibody against SARS‐CoV‐2 was measured. Propensity scores were calculated via logistic regression to transform the probability of having received either BNT162b2 or mRNA1273 vaccine, and a model was developed. We enrolled 623 SOT recipients. In the propensity score‐matched analysis, 100 recipients were selected for BNT162b2 and 100 for mRNA1273. SARS‐CoV‐2 anti‐spike protein antibody positivity with BNT162b2 versus mRNA1273 at 3 weeks after the first dose, 1 month after the second dose, 3 months after the second dose, and 6 months after the second dose were 10% versus 19% (P = .07), 51% versus 58% (P = .30), 74% versus 88% (P = .01), and 78% versus 87% (P = .13), respectively. We conducted a propensity score‐matched comparison of BNT162b2 and mRNA1273 vaccines as the primary series of COVID‐19 vaccines in SOT recipients. We found significantly better immunogenicity with the mRNA1273 vaccine than with BNT162b2.


  • Influenza vaccine viruses and the development of seasonal vaccines: A Japanese perspective

    by Hiroaki Kato, Takao Hozawa, Wakaba Fukushima, Eri Nobusawa, Yoshio Hirota


  • Open Access

    Effectiveness of Live Attenuated Varicella-Zoster Vaccine in Adults Older than 50 Years in Japan: A Retrospective Cohort Study

    by Kazuhiro Matsumoto, Satoko Ohfuji, Kana Inohara, Masateru Akechi, Hiroko Kumashiro, Motoki Ishibashi, Shin Irie, Yoshio Hirota

    Background: In Japan, freeze-dried live attenuated varicella-zoster vaccine BIKEN is available for adults aged ≥50 years to prevent herpes zoster (HZ). A prospective cohort study of 1200 healthy adults and 300 patients with underlying illness confirmed vaccine safety between 2016 and 2017. However, evidence of vaccine effectiveness (VE) is limited. Methods: VE against HZ and postherpetic neuralgia (PHN) was evaluated in the vaccinated cohort of the previous safety study in a follow-up study between 2021 and 2022 and compared with unvaccinated family members. Self-administered questionnaires determined retrospective experiences of HZ and PHN diagnosis. Logistic regression estimated the VE by calculating the outcome odds ratio (OR) in vaccinated vs. unvaccinated groups: VE = (1 − OR) × 100(%). Results: Overall, 1098 vaccinated and 518 unvaccinated subjects were analysed. Between 2016 and 2022, 26 vaccinated (2.4%) and 22 unvaccinated (4.2%) subjects reported HZ diagnosis, and 3 vaccinated (0.3%) and 2 unvaccinated (0.4%) subjects reported PHN. Adjusted VE against a clinical diagnosis was 41% for HZ [−6% to 67%], with marginal significance, and 16% [−408% to 86%] for PHN. Stratification by age, sex, or comorbidities had an adjusted VE against HZ of ~40%, which was similar between strata. Conclusion: Freeze-dried live attenuated varicella-zoster vaccine reduces the risk of HZ regardless of age, sex, or comorbidities.